Diabetes Information

Benfotiamine - A New Tool In Preventing Diabetic Complications?


Benfotiamine made headlines globally in 2003 when researchers released information about a study that was conducted at The Einstein College of Medicine in New York. The bottom line of this study was that a substance of the allithiamine group of the naturally occurring thiamine-derived compounds had positive effects on neuropathy, retinopathy and nephropathy and heart/circulatory problems in diabetics.

Benfotiamine research has suggested that there are beneficial effects for diabetics and non-diabetics also. These benefits include sciatica, vascular health, general nerve health, lower blood pressure, grant cellular protection, anti-aging, fibromyalgia, prevention of lactic acidosis, and treatment for Alzheimer's disease. Any condition that is the result of a thiamine deficiency will also respond quite well to benfotiamine. Of course, any bodily function that is improved by a therapeutic level of thiamine will certainly be enhanced by benfotiamine, since benfotiamine is perhaps the most effective form of thiamine.

Benfotiamine, a derivative of thiamine (vitamin B1), was an invention of Japanese scientists and there is a U.S. patent on benfotiamine that was entered by the Japanese back in 1962. Japanese benfotiamine is considered the purest source of bulk benfotiamine and is favored by manufacturers globally who insist on the highest quality in their benfotiamine product.

The safety of benfotiamine use has been proven over 12 years of use in Europe for the treatment and prevention of diabetic complications among others. The original Japanese patent on benfotiamine gave information that it is even less toxic than common vitamin B1 (thiamine hydrochloride usually). Orally ingested vitamin B1 has a long history of use as an oral supplement without reported adverse effects. Due to its therapeutic action in some frequently observed clinical syndromes, thiamine hydrochloride has been advised and used over a long period of time. There are no reports of adverse effects of oral thiamine, even at dosages of several hundred milligrams a day (SCOGS, 1978; DHEW, 1979; Marks, 1989).

Benfotiamine has a very good safety record. To date, there has been no reports of any known, negative interactions with any medications. To the contrary, some medications actually can cause a thiamine deficiency in some people and benfotiamine could correct this serious situation.

Many researchers, medical experts, doctors, podiatrists and many medical publishers recommend benfotiamine for neuropathy, retinopathy nephropathy, heart/circulatory complications and B1 deficiencies. Any in depth study on the web will produce physicians, naturopaths, neurologists, optometrists, chiropractors, etc. who have very positive feelings about the effectiveness and potential of benfotiamine in terms of the research done to date on this important tool in the arsenal against neuropathy, retinopathy and beneficial for the heart and circulatory system. We have professional healthcare providers from all of these disciplines which shows the confidence the medical community has in the purity and bioavailability of our benfotiamine product.

Dr. David Williams, publisher of "Alternatives Newsletter", wrote an in depth article concerning benfotiamine in his May, 2004 issue. This article is an eye opener in terms of how effective benfotiamine can be for many health conditions. If possible, it would be beneficial for any interested reader to take a look at this article. For more information about this article you may contact the author below.

Dr Paul Chous is another medical professional who sees the merits of benfotiamine:

"I suspect strongly that benfotiamine will mitigate (or, hopefully, prevent) DRT in humans, but the burden of proof has not yet been met. The case for symptomatic relief of neuropathy symptoms is, of course, more tangible." http://www.emuhealthproducts.com/drchous.html

In conclusion, the consensus for benfotiamine is very positive and are worth investigating. If you or anyone you know is a diabetic, the great possibility of developing diabetic complications over time makes benfotiamine a viable tool in the arsenal for protection. If they are already experiencing complications such as neuropathy, retinopathy, and others, they will benefit from possible reduction in the progression along with pain relief in terms of peripheral neuropathy and other neuropathies.

Zach Malott is CEO of Brentwood Health International, a nutritional supplement company involved in distribution and supplying wholesale, retail and end users.

Mr. Malott is available to discuss the research as it applies to benfotiamine in the treatment and prevention of diabetic complications such as neuropathy and retinopathy.

He can be reached at:

Phone: 505.354.0526

Website: http://www.emuhealthproducts.com


MORE RESOURCES:

dBTechno

Novo Nordisk Diabetes Drug Victoza Gets EU Approval
Wall Street Journal
Victoza, also known as Liraglutide, belongs to a relatively new kind of diabetes drug class known as GLP-1 analogues. In contrast to conventional treatment ...
Novo Nordisk wins Europe OK for diabetes drugMarketWatch
EU Approves Novo Nordisk's Drug For Type 2 Diabetes TreatmentAHN
EU Commission Approves Victoza for Diabetes PatientsdBTechno
Reuters -Wall Street Journal
all 32 news articles »


Health Tip: Understanding Pre-Diabetes
Forbes
(HealthDay News) -- Before some people develop full-blown diabetes, their blood sugar is above normal, but not high enough to qualify for a diagnosis of ...
Discovery may help diabetics control blood sugarABC7Chicago.com

all 7 news articles »



HealthJockey.com

Kids With Type 1 Diabetes Often Overweight
Atlanta Journal Constitution
THURSDAY, July 2 (healthday News) -- Children with type 1 diabetes are more likely to be overweight than those without the disease, increasing their risk of ...
Patients Suffering from Diabetes Now Have the Option to Suffer No ...PR Web (press release)
Natural Compound Stops Retinopathy, Study SuggestsScience Daily (press release)
Natural Compound Can Stop the Development of Retinopathy It's one ...Softpedia
Times of the Internet
all 32 news articles »


CBS News

CORRECT: FDA To Patients: Stay On Lantus Despite Concerns
Wall Street Journal
Studies published Friday in Diabetologia, the journal of the European Association for the Study of Diabetes, showed a possible link between Lantus and ...
FDA Tells Patients to Stick With Diabetes Drug Linked to CancerAtlanta Journal Constitution
Diabetics urged to stay on popular insulin LantusReuters
Growing concern over diabetes medicationWKYC-TV
WebMD -Bloomberg -News & Observer -dBTechno
all 346 news articles »


'Jumping Gene' Diminishes The Effect Of New Type 2 Diabetes Risk Gene
Science Daily (press release)
ScienceDaily (July 4, 2009) — Research led by the German Institute of Human Nutrition (DIfE) has identified a new gene associated with diabetes, ...

and more »


New York Times

Experiment seeks to head off Type 1 diabetes
The Associated Press
"If we're right, that is what's going to stop Type 1 diabetes," said Dr. David Finegold as he watched the blisters appear — one to match each of four shots ...
Ask Questions About Type 1 and ExerciseNew York Times
Growth rate associated with increased type I diabetes in at risk ...Examiner.com
Researchers say obesity, diabetes interfere with productivityWorkers Comp Forum
Journal Gazette and Times-Courier -Express & Echo -Attorney at Law -New York Times Blogs
all 148 news articles »


dBTechno

Health Buzz: Diabetes Drug Setback and Other Health News
U.S. News & World Report
The US Food and Drug Administration postponed the approval of alogliptin, a drug to treat type 2 diabetes. Shares in Takeda, the drug's maker and Japan's ...
Takeda shares hurt by diabetes drug US setbackReuters
Takeda Seeks Japan Approval Of Therapy With New Diabetes DrugWall Street Journal
FDA wants additional study of diabetes drugChicago Tribune
Bizjournals.com -Reuters -Wall Street Journal
all 84 news articles »


Interferon Alpha Can Delay Full Onset Of Type I Diabetes, Phase II ...
Science Daily (press release)
The results of the Phase II trial are published July 1 in Diabetes Care, a journal of the American Diabetes Association. "It shows a strong trend in ...
Interferon May Hold The Key To Fighting Type I DiabetesChattahBox

all 9 news articles »


Exercise: A Diabetes Fighter?
Tampa Tribune
Skip exercise now, pay later: That's the warning from a study that found that younger people who didn't exercise were more likely to develop diabetes in 20 ...

and more »

Google News

home | site map
© 2006